Influence of CYP2D6, CYP3A4 and CYP2C19 Genotypes on Recurrence of Plasmodium vivax
Authors:
Open Access
- 18 March 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Tropical Diseases
- Vol. 3
Abstract
Background: The influence of the CYPs (cytochrome P-450) in the success of antimalarial therapy remains uncertain. In this study, the association of CYP2D6, CYP2C19 and CYP3A4 polymorphisms and predicted phenotypes with malaria recurrence was investigated.Methods: After diagnosis of vivax malaria, individuals treated at a reference center in Manaus were followed up for 180 days. Patients were separated into two groups: a recurrence group and a non-recurrence group. Genotyping of CYP2D6, CYP2C19 and CYP3A4 was performed using a TaqMan™ assay and real-time PCR.Findings: The frequencies of decreased-function and normal-function alleles and phenotypes for all CYPs were similar between the groups, except for the CYP2D6*2xN allele (p=0.047) and the CYP2D6 gUM phenotype (p=0.057), which were more frequent in individuals without recurrence. Despite this, the CYP2D6, CYP2C19 and CYP3A4 genotypes had no association with an increased risk of recurrence. CYPs polymorphisms also had no influence in parasite clearance, neither in the time nor the number of recurrence episodes. MAINConclusion: This prospective cohort study demonstrated that CYP2D6, CYP2C19 and CYP3A4 polymorphisms have no influence on malaria recurrence. Nonetheless, our findings suggest that the CYP2D6 predicted ultrarapid phenotype was less susceptible to recurrence, and that patients with the CYP2D6 gUM phenotype are less susceptible to primaquine failure. Additional investigation of pharmacogenetics and pharmacokinetics are needed before implementing CYP analysis to better orientate individualized radical treatment of vivax malaria in reference centers that treat patients with multiple recurrences.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (MCTIC/CNPq 2018)
- Fundação de Amparo à Pesquisa do Estado do Amazonas (PAPAC (#005/2019) , PCTI-EMERGESAÚDE/AM (#005/2020))
This publication has 45 references indexed in Scilit:
- Pharmacokinetic Interactions between Primaquine and ChloroquineAntimicrobial Agents and Chemotherapy, 2014
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 UpdateClinical Pharmacology & Therapeutics, 2014
- Primaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax MalariaNew England Journal of Medicine, 2013
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 UpdateClinical Pharmacology & Therapeutics, 2013
- Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the “Missing Heritability” ProblemFrontiers in Genetics, 2013
- CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquineMalaria Journal, 2012
- Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among BraziliansThe Pharmacogenomics Journal, 2010
- Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformationAnalytical and Bioanalytical Chemistry, 2008
- Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxisEuropean Journal of Clinical Pharmacology, 2002
- Análise da freqüência de recaídas de malária por Plasmodium vivax em região não endêmica (São Paulo, Brasil)Revista do Instituto de Medicina Tropical de São Paulo, 1991